Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UCB Board/Management Information 2018

Mar 23, 2018

4017_rns_2018-03-23_e44ddd02-7cea-476a-bdf4-c6a70579b6d0.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Kay Davies

Kay Davies is the Dr. Lee's Professor of Anatomy in the Department of Physiology, Anatomy and Genetics at the University of Oxford.

Her research interests lie in the molecular analysis and development of treatment for human genetic disease, particularly, Duchenne muscular dystrophy (DMD) and the application of genomics for the analysis of neurological disorders. She has published more than 400 papers and won numerous awards for her work. She is co-founder of Summit Therapeutics which aims to develop a therapy for DMD and also has an interest in the ethical issues associated with genetics research. She is a founding fellow of the UK Academy of Medical Sciences and was elected a Fellow of the Royal Society in 2003. She is a Director of the Biotech Growth Trust, a Director of Genome England, Director of Genome Research Ltd. She was a Governor of the Wellcome Trust 2008-17 and Deputy Chairman 2013-2017.

Professor Davies was made Dame Commander of the British Empire for services to science in 2008. She has also been involved as independent scientific advisor on UCB's Science Advisory Board since 2012 and is member of the UCB's Governance, Nomination and Compensation Committee ("GNCC") as from 2017.